<DOC>
	<DOCNO>NCT00697918</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety RWJ-333369 dos 200-800 mg/day Korean Japanese patient complete precede study ( 333369-KJ-02 ) .</brief_summary>
	<brief_title>Long Term Effectiveness Safety Study RWJ-333369 Adjunctive Therapy Korean Japanese Patients With Partial Onset Seizures</brief_title>
	<detailed_description>Despite introduction new antiepileptic drug overseas clinical setting 1990 's , still exist patient control seizures , thus advent new antiepileptic drug desire . This multicenter , open-label , extension study patient complete precede study ( 333369-KJ-02 ) schedule continue study drug approve . This study consist Period 1 ( 1 year ) Period 2 ( Japan ; plan continue drug approve Primary objective study evaluate long-term safety ( Adverse event , Lab test , Electrocardiogram , Vital sign , Pregnancy test , Physician Withdrawal Checklist ) RWJ-333369 dose 200-800 mg/day patient complete precede study . Secondary objective study evaluate long-term effectiveness RWJ-333369 dos 200-800 mg/day patient complete precede study . Period 1 : RWJ-333369 start 400 mg/day . RWJ-333369 100 mg tablet 200 mg tablet orally administer noncarbonated water twice daily . The dose adjust 200 mg/day 800 mg/day base effectiveness tolerance . Period 2 : The dose adjust 200 mg/day 800 mg/day base effectiveness tolerance .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<criteria>Patients precede study ( 333369KJ02 ) complete DoubleBlind Treatment Phase precede study Considered ineligible study patient investigator</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Partial onset seizure</keyword>
	<keyword>Adjunctive therapy</keyword>
</DOC>